Navigation Links
CNS Response, Inc.: Poster Session on Referenced-EEG Guided Medication to Be Presented at the American Psychiatric Association 161st Annual Meeting

COSTA MESA, Calif., May 6 /PRNewswire-FirstCall/ -- CNS Response, Inc. (OTC Bulletin Board: CNSO) announced today that Dr. James Greenblatt, M.D., Chief Medical Officer, Walden Behavioral Care Inpatient Psychiatry and Eating Disorder Programs, will present a poster session at the American Psychiatric Association (APA) 161st Annual Meeting. The poster presentation, titled "Referenced-EEG Guided Medication Predictions in Treatment Refractory Eating Disorder Patients," will take place on Wednesday, May 7, 2008 from 3:00 p.m. to 5:00 p.m., ET.

The APA Annual Meeting will be held in Washington, DC from May 3-8, 2008. Further information on the conference can be found at

About CNS Response

CNS Response is a life-sciences data company whose patented system provides treatment guidance to psychiatrists and other physicians for patients with behavioral (mental or addictive) disorders. This technology allows CNS Response to create and provide simple reports ("rEEG(R) Reports") that specifically guide physicians to treatment strategies based on the patient's own physiology.

rEEG(R) utilizes traditional electroencephalography (EEG) in conjunction with a normative database and a proprietary clinical (symptomatic) database to identify the following: (1) medication classes most likely to be needed; and (2) medications within these classes with the most probable treatment potential for each patient. Reports are provided to physicians in a relationship analogous to that of a reference laboratory. Prospective, retrospective and field studies of treatment-resistant patients have reported treatment success of 70% or greater in managed care, outpatient psychiatric and residential substance abuse clinical settings.

In addition to providing analytical support to physicians, CNS Response is also an aid to pharmaceutical developers, who can use rEEG to (1) stratify study populations to improve the success of FDA clinical trials; (2) provide insight on effective therapeutic dosing of investigational drugs; (3) identify additional indications for psychiatric medications; (4) provide insight into effective drug combinations; and (5) discover opportunities for decision analytics and support. In addition to these applications, CNS Response continues to investigate the use of rEEG analysis for development of proprietary pharmaceutical opportunities.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995

Except for the historical information contained herein, the matters discussed are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These statements involve risks and uncertainties as set forth in the Company's filings with the Securities and Exchange Commission. These risks and uncertainties could cause actual results to differ materially from any forward-looking statements made herein.


Investor Relations:

Sara Ephraim

(646) 536-7002


Jason Rando / Jennifer Saunders

(646) 536-7033 / 7011

SOURCE CNS Response, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. CNS Response, Inc. Names William E. Bunney, Jr., MD to Scientific Advisory Board
2. CNS Response, Inc: rEEG(R) Research to be Presented at 38th National Council Conference
3. CNS Response, Inc. Enters Agreement to Introduce rEEG(R) Platform to Managed Behavioral Health Organization
4. Bacterial toxin closes gate on immune response, Penn researchers discover
5. CNS Response, Inc. Names Henry T. Harbin, MD to Board of Directors
6. CNS Response, Inc. Modifies rEEG(SM) Trial Protocol for Treatment-Resistant Depression Study
7. CNS Response, Inc. Appoints George C. Carpenter IV to Position of President
8. Panomics Inc.: Recipient of the Frost & Sullivan 2007 United States Drug Discovery Technologies Entrepreneurial Company of the Year Award
9. Biomist Inc.: Health Officials Discover New Technology to Kill Superbug MRSA
10. Pennsylvania Dental Association Announces Winners of Annual Statewide Third-grade Student Poster Contest
11. Scientific poster abstracts from the 24th annual meeting of the American Academy of Pain Medicine
Post Your Comments:
(Date:11/24/2015)... ... November 24, 2015 , ... In an article ... variables that determine which patients are or are not eligible for bariatric surgery. The ... BMI over 40, are more than 100 pounds overweight, or have a BMI of ...
(Date:11/24/2015)... ... November 24, 2015 , ... It takes only three to five seconds to ... that the first impression be positive and reflects business values. If a client starts ... or want to return. They will also share their thoughts about a business with ...
(Date:11/24/2015)... ... 24, 2015 , ... Cancer patients, survivors, caregivers, family members ... live taping of the next CURE Connections® video series on Saturday, ... Symposium at Georgetown University Hotel & Conference Center in Washington, D.C. , CURE ...
(Date:11/24/2015)... ... November 24, 2015 , ... Aided by seed funding from the Ron Foley ... to yield insights into how to detect and treat pancreatic cancer (PC). , ... small, non-coding RNA molecules (ncRNA), genetic material that is present in the blood of ...
(Date:11/24/2015)... ... 24, 2015 , ... Sir Grout of Baltimore is proud ... The award recognizes good companies for excellence in service and a commitment to ... hard surface restoration company earned this recognition after a thorough review by the ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... 2015 Abaxis, Inc. (NasdaqGS: ABAX ), ... for the medical, research, and veterinary markets worldwide, announced ... will present at the 27 th Annual Piper ... 11:30 a.m. ET. The conference will be held at ... York City . Abaxis, Inc. is ...
(Date:11/24/2015)... , Nov. 24, 2015  Eyewear brand Revo ... with U2 lead singer and activist Bono as part of ... vision impairment and blindness in more than 5 million people ... Revo will donate $10 from the sale of every pair ... to a total of $10 million to the "Buy Vision, ...
(Date:11/24/2015)... , Nov. 24, 2015   Mast Therapeutics, Inc. ... its molecular adhesion and sealant technology (MAST) platform to ... and stroke, today announced that the Company,s Chief Executive ... the Piper Jaffray 27 th Annual Healthcare Conference ... at the New York Palace hotel in ...
Breaking Medicine Technology: